Geode Capital Management LLC Purchases 21,789 Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)

Geode Capital Management LLC increased its position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 4.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 477,269 shares of the company’s stock after buying an additional 21,789 shares during the period. Geode Capital Management LLC owned about 1.05% of Verrica Pharmaceuticals worth $334,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Barclays PLC raised its stake in Verrica Pharmaceuticals by 404.6% during the 3rd quarter. Barclays PLC now owns 31,341 shares of the company’s stock valued at $45,000 after purchasing an additional 25,130 shares during the period. Jane Street Group LLC grew its holdings in Verrica Pharmaceuticals by 106.5% during the 3rd quarter. Jane Street Group LLC now owns 69,872 shares of the company’s stock valued at $101,000 after buying an additional 36,028 shares in the last quarter. State Street Corp raised its position in shares of Verrica Pharmaceuticals by 13.5% during the third quarter. State Street Corp now owns 512,821 shares of the company’s stock valued at $744,000 after buying an additional 61,041 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Verrica Pharmaceuticals by 975.2% in the fourth quarter. Rhumbline Advisers now owns 266,093 shares of the company’s stock worth $186,000 after buying an additional 241,344 shares in the last quarter. Finally, Sovran Advisors LLC bought a new position in shares of Verrica Pharmaceuticals during the fourth quarter worth $267,000. Hedge funds and other institutional investors own 42.45% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on VRCA. HC Wainwright reiterated a “neutral” rating on shares of Verrica Pharmaceuticals in a report on Tuesday, April 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, April 9th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $9.50.

Verrica Pharmaceuticals Stock Performance

Shares of VRCA opened at $0.47 on Friday. The stock has a market capitalization of $43.36 million, a PE ratio of -0.26 and a beta of 1.68. The company’s fifty day moving average is $0.53 and its 200 day moving average is $0.77. Verrica Pharmaceuticals Inc. has a fifty-two week low of $0.38 and a fifty-two week high of $11.41.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.01. Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%. The company had revenue of $0.34 million for the quarter, compared to analysts’ expectations of $1.30 million. As a group, research analysts forecast that Verrica Pharmaceuticals Inc. will post -1.46 earnings per share for the current year.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.